A Study With NLY01 in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2020-12-04
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2
diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic
effects on glycemic control.